Atlas Trials

Cogent Biosciences, Inc.

14 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Cogent Biosciences, Inc.

RecordFirmDate
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors (NCT07383506)Cogent Biosciences, Inc.2026-06-01
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors (NCT07361562)Cogent Biosciences, Inc.2025-12-30
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors (NCT06777316)Cogent Biosciences, Inc.2025-01-22
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis (NCT05186753)Cogent Biosciences, Inc.2022-06-27
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors (NCT05208047)Cogent Biosciences, Inc.2022-04-14
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis (NCT04996875)Cogent Biosciences, Inc.2021-11-09
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03266692)Cogent Biosciences, Inc.2018-02-22
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma (NCT03189836)Cogent Biosciences, Inc.2017-10-04

Track Cogent Biosciences, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.